On April 3, 2026, the Consumer Technology Association (CTA) unveiled CTA-2134, the first-ever voluntary standard for women's health technologies, at its Innovation House on Capitol Hill. Titled "Best Practices and Performance Requirements for Women's Health Technologies," the framework establishes baseline expectations for how femtech products should be designed, tested, and deployed — addressing a sector projected to exceed $200 billion globally by 2033.

Why It Matters

The femtech sector has exploded in size — $314 million in funding in January 2026 alone — but has operated without shared design or data standards, leading to products built on datasets that often excluded non-white, non-cisgender, and non-reproductive-age women. CTA-2134 is the first attempt by a major technology trade body to establish common benchmarks, and its emphasis on inclusive data practices and privacy could reshape how the next generation of period trackers, menopause apps, pelvic health devices, and fertility platforms are built. For the sexual wellness industry specifically, the standard's explicit instruction not to reduce women's health to reproduction signals a maturing market that treats sexual function, pleasure, and holistic wellness as equally valid design parameters.

CTA-2134 covers four key areas: design and performance requirements, data management practices, privacy protections, and cybersecurity standards. Most notably, the standard mandates that "data labeling shall not reduce women's health to reproductive metrics alone" and recommends machine learning models use data "annotated with attributes that enable performance analysis across subgroups while maintaining privacy." In plain terms: femtech companies should stop treating women's health as synonymous with fertility tracking and start designing for the full spectrum of women's biology and life stages.

The guidelines stress inclusive design, requiring that companies build products using data from diverse populations — including women of color, LGBTQ+ individuals, those with disabilities, and those with chronic conditions. CTA President Kinsey Fabrizio stated the initiative aims to ensure that "the next generation of digital health technologies delivers more insights and better outcomes for millions of women." The standards were developed in collaboration with industry stakeholders, according to Kerri Haresign, CTA's senior director of technology and standards.

Critically, CTA-2134 is voluntary — the CTA is a trade association, not a regulatory body. Companies can choose to adopt the standard or ignore it entirely, and there is no certification or enforcement mechanism. Still, the existence of a formal industry benchmark could influence procurement decisions, insurance coverage conversations, and future FDA guidance, particularly as femtech devices increasingly seek regulatory clearance.

Sources

Update — 2026-04-04

Initial entry — story first created.